Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MEDI-573 + Vistusertib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MEDI-573 | Dusigitumab | IGF1/2 Antibody 2 | Dusigitumab (MEDI-573) is an antibody that targets IGF-1 and IGF-2, resulting in decreased IGF-mediated signaling and potentially leading to decreased tumor growth (PMID: 25193511). | |
| Vistusertib | AZD2014|AZD-2014 | mTOR Inhibitor 51 | Vistusertib (AZD2014) is an ATP-competitive inhibitor of mTOR, which may result in tumor growth inhibition (PMID: 23375793, PMID: 31707687). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|